Studies obinutuzumab-based treatment for untreated follicular lymphoma
Observes how obinutuzumab-based therapy works and its safety in adults newly diagnosed with follicular lymphoma.
Plain-language title generated from the registry record
Registry title: A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT05899621
- Record updated
- 12 June 2023
- Original description
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphomaRead full original descriptionShow less
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma
Inclusion: Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification; Treatment naive; Age ≥ 18 years; Indications for treatment confirmed; Must has measurable lesion in CT or PET-CT prior to treatment; Considered suitable for GR, GB or GCHOP regimens; Informed consented.
Exclusion: Any drug contraindication in the treatment plan; HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive; Transformed follicular lymphoma or 3B follicular lymphoma; Central nervous system or meninges involved; Patients judged by other researchers to be unsuitable for inclusion in the study.